CA-DEGREED
23.6.2022 21:15:12 CEST | Business Wire | Press release
Degreed , the global innovator in professional lifelong learning chosen by more than one in three Fortune 50 companies, today announced the acquisition of talent academy platform, Learn In , and the return of Co-founder David Blake as CEO. Blake was previously the Co-founder and CEO of Learn In.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005917/en/
Learn In helps companies establish internal talent academies that bring together all the resources needed for building a highly skilled workforce, including the longer journey of developing deep skills. Learn In’s core features supplement those of the category-defining Degreed LXP (Learning Experience Platform), including a prepaid learning stipend card, a world-class skills marketplace and custom program builder, a tuition benefits manager, and dedicated coaching.
“A corporate capability academy goes beyond ‘a library of content,’” said global industry analyst and CEO of the Josh Bersin Company, Josh Bersin . “It’s a place people go to advance their job-related capabilities. It goes beyond technical and functional skills and focuses on the real business capabilities a company needs to thrive.”
Degreed plus Learn In will unify the broader range of development options people use, spanning daily learning to long-term upskilling for individual career growth and innovation within organizations.
Blake’s plans for the future of Degreed were divergent with the current direction, so an amicable decision was made that he return to the company as CEO and execute that vision.
Degreed thanks Dan Levin for the progress he has driven and his stewardship of the Degreed mission over the past 15 months, and is grateful for his accomplishments, including increasing our client base, establishing operational rigor for scale, and significantly expanding our partner ecosystem and overall global footprint.
“Businesses that can quickly build effective talent are the ones that will be able to deliver on strategic business goals,” said David Blake, Co-founder and CEO of Degreed . “Just as Degreed created the LXP market, Learn In has begun for talent academies. Now together, we have the product and technology to help our customers deliver business capabilities at scale with continued innovation in the learning and skills space.”
“At BMO, our strategy is to build a digitally-enabled bank that’s ready for the future. This means we need to equip employees with the skills they need for their job, their career, for the future of work, and as they follow their personal passions,” says Gina Jeneroux, Chief Learning Officer at BMO Financial Group . “As Degreed and Learn In come together, it will offer a more integrated opportunity for organizations like ours to engage employees and build a broader range of skills—from curious, ‘in-the-moment’ learning through to deeper reskilling and credentials.”
This is the fourth acquisition for Degreed, and Blake re-joins a seasoned Degreed leadership team from Bank of America, Mastercard, Danone, LinkedIn, Adobe, SAP and Saba.
About Degreed
Degreed empowers innovation through learning. As a changemaker on a global scale, we work with one in three Fortune 50 companies to spark a culture of learning across their enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need – through individual, collaborative and experiential modes of learning – to drive individual and business results. Founded in 2012, Degreed is headquartered in Pleasanton, California, with users spanning 191 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
About Learn In
Learn In helps companies establish talent academies that steer all the resources needed for building a highly skilled workforce. HR, Talent and L&D leaders use Learn In to modernize access to learning budgets and world-class programs, and to simplify the delivery of custom programs to employee groups. Learn In’s core features include a tuition benefits manager, a prepaid learning stipend card, a world-class program marketplace and custom program builder, and dedicated coaching. Now every employee can build deeper skills precisely aligned to company needs. Co-founded by the founders of Degreed, Learn In is backed by leading edtech & future-of-work investors, including Firework Ventures, Kickstart Fund, Album, GSV, and Village Global, and has been covered in CNBC, USA Today, EdTechReview, EdSurge, Fast Company, and Techcrunch.
Learn more about Learn In: Website | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005917/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom